THE PROJECT
MIRAMOON pharma
is a drug discovery spin-off
Comming from Biodonostia Health Research Institute and University of the Basque Country, the company aim is to develop new drugs “First in Class” based on the interaction with new protein receptor that modulates the ryanodine calcium channel.
MIRAMOON pharma
is a drug discovery spin-off
Comming from Biodonostia Health Research Institute and University of the Basque Country, the company aim is to develop new drugs “First in Class” based on the interaction with new protein receptor that modulates the ryanodine calcium channel.
This target is totally new and its modulation opens the door to the development of drugs with a new mechanism of action that can treat a series of diseases that are currently intractable.
OUR TECHNOLOGY
A family of molecules patented with therapeutic potential for a number of neurodegenerative diseases that have in common a change in intracellular calcium flows.
Applications for:
ADVANTAGES
Topical administration
Able to reach the retina without coming into contact with the rest of the general metabolism.
THE TEAM
Company
The company is headed by a first-rate team with experience in drug development, neuromuscular diseases, venture capital and licensing.
Advisors
Our advisors are renowned scientists in the world of medical chemistry and entrepreneurs with a long history working and advising the main players in pharmaceutical companies.
“First-rate team with experience in drug development which will ensure an efficient management”
“First-rate team with experience in drug development which will ensure an efficient management”
Company
The company is headed by a first-rate team with experience in drug development, neuromuscular diseases, venture capital and licensing.
Advisors
Our advisors are renowned scientists in the world of medical chemistry and entrepreneurs with a long history working and advising the main players in pharmaceutical companies.
CONTACTS
Av. Tolosa 72
20018 y Donostia/ San Sebastián
Spain